A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Paweł Wiechno Piotr L Chlosta |
| Publication date | November 6, 2013 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |